Genetics and Genetic Testing in Congenital Heart Disease by Cowan, Jason R. & Ware, Stephanie M.
1 
Review 
Genetics and Genetic Testing in Congenital Heart Disease 
Jason R. Cowan1,2, Stephanie M. Ware2* 
1University of Cincinnati College of Medicine, Cincinnati, OH and 2Department of Pediatrics and Herman 
B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 
Jason Cowan, MS 
Indiana University School of Medicine 
1044 W. Walnut Street 
Indianapolis, IN 46202 
Phone: 317-274-8939 
Email: cowanja@iupui.edu 
(*) Corresponding author: 
Stephanie M. Ware, MD, PhD 
Indiana University School of Medicine 
1044 W. Walnut Street 
Indianapolis, IN 46202 
Phone: 317-274-8938 
Fax: 317-274-8679 
Email: stware@iu.edu 
This is the author's manuscript of the article published in final edited form as: 
Cowan, J. R., & Ware, S. M. (2015). Genetics and Genetic Testing in Congenital Heart Disease. Clinics in Perinatology, 
42(2), 373–393. http://doi.org/10.1016/j.clp.2015.02.009
2 
 
TABLE OF CONTENTS SYNOPSIS: 
In this review we provide a general overview of key morphologic, molecular, and signaling mechanisms 
relevant to heart development before summarizing overall progress in the molecular genetic analyses of 
congenital heart defects (CHDs) and providing current recommendations for clinical application of genetic 
testing. CHDs represent the single largest cause of infant morbidity and mortality worldwide and are, 
consequently, a significant source of global economic burden. Advancements in genetic testing 
technologies have facilitated improved diagnostics and identification of novel genetic causes, which can 
encompass single-gene mutations, complex chromosomal abnormalities, submicroscopic 
rearrangements, or whole chromosome aneuploidies. While many CHDs occur in isolation, significant 
proportions are associated with extra-cardiac malformations as components of wider genetic syndromes. 
For these reasons, genetic evaluation and counseling are considered integral components of risk 
assessment and clinical care.  
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ABSTRACT: 
Congenital heart defects (CHDs) are structural abnormalities of the heart and great vessels that 
are present from birth. The presence or absence of extra-cardiac anomalies has historically been used to 
identify patients with possible monogenic, chromosomal, or teratogenic CHD etiologies. These 
distinctions remain clinically relevant, particularly with regard to management; however, identification of 
genetic causes in patients with presumably non-syndromic CHD indicates that isolated CHD can also be 
genetic in origin. In recent years, the field of cardiac genetics has benefited from a growing understanding 
of the complex molecular mechanisms underpinning heart development, and the extreme genetic 
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heterogeneity of CHD is increasingly appreciated. Progress has been largely supported by improvements 
in genetic testing technology derived from worldwide efforts to accurately and economically characterize 
the full breadth of human genomic variation.  The last fifteen years in particular have witnessed 
emergence and refinement of novel cytogenetic and sequencing technologies, which have proven to be 
enormously effective tools for both diagnosis and identification of novel CHD-causing genes. These 
advancements have led to an increasing need for cardiac care providers to be well versed in the 
molecular genetic origins of CHD and to have working knowledge of the benefits and limitations of 
available testing methods. In this review, we provide a general overview of key morphologic, molecular, 
and signaling mechanisms relevant to heart development before summarizing overall progress in the 
molecular genetic analyses of CHDs and current recommendations for clinical application of genetic 
testing. Particular emphasis is placed on the utility and limitations of chromosomal microarray analyses 
(CMAs) and on emerging clinical roles for whole exome sequencing (WES) and other next-generation 
sequencing (NGS) technologies. 
 
KEY POINTS: 
• Congenital heart defects (CHDs) are the largest contributor to worldwide infant morbidity and mortality. 
• Known genetic causes encompass single-gene mutations, complex chromosomal abnormalities, 
submicroscopic rearrangements, and whole chromosome aneuploidies. 
• Significant proportions of CHDs are associated with extra-cardiac malformations and/or occur as 
components of a genetic syndrome.  
• Advancements in genetic testing technologies have facilitated improved diagnostics and identification 
of novel genetic causes of CHD. 
• Genetic consultation and counseling is an integral component of risk assessment and clinical care. 
Evaluation by a geneticist is essential when a possible syndrome is suspected. 
 
INTRODUCTION: 
 The impact of CHDs is profound. With a traditionally cited incidence of 8 per 1000 live births 
(~1%), and a need for expert cardiologic intervention in 3 of every 1000 newborns1, CHDs are both the 
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single largest cause of infant morbidity and mortality worldwide and a significant source of global 
economic burden2, 3. Taking into account very high rates of CHDs in spontaneous abortuses4, and subtle 
or subclinical abnormalities in another 1-2% of patients5, the true overall incidence of CHDs is 
undoubtedly much greater. While these figures effectively convey the large global clinical impact of 
CHDs, they fail to communicate both the enormous diversity of phenotypes among affected individuals 
and the emerging understanding of the complexity of genetic and developmental etiologies.  
Research into the mechanisms that regulate heart development has advanced significantly in the 
last twenty years. Studies employing a diverse array of model organisms including mice, frogs, and 
zebrafish, have facilitated major insight into normal and abnormal cardiogenesis. Furthermore, systems 
biology approaches designed to assess functional convergence of causative CHD genes and associated 
transcriptional responders (genes with altered cardiac expression) have suggested that multiple CHD risk 
factors are more likely to act on different components of a common functional network than to directly 
converge on a common genetic or molecular target 6, 7. These findings, coupled with an ever-expanding 
list of CHD-associated gene mutations8, chromosomal abnormalities9, environmental causes10, 11, and 
epigenetic insults12, 13 hint at a significant complexity to both normal heart development and CHD 
pathogenesis. In the following section, we describe current understanding of the major embryologic 
events that shape the developing heart. We then provide a brief overview of key signaling and molecular 
concepts relevant to these developmental processes. Readers desiring additional details are directed to 
recent comprehensive reviews14-21. 
 
Overview of heart development: 
Cell lineage is an important concept for heart development as distinct lineages support the 
development of specific cardiac compartments such that structural anomalies may result from 
dysregulation of a single cell lineage, multiple lineages, or specific inductive interactions between 
lineages. During the second and third weeks of human development, two mesodermal subpopulations, 
the first (FHF) and second (SHF) heart fields, contribute cells to the developing heart. While the FHF will 
ultimately contribute to the left ventricle and portions of the atria and right ventricle, the SHF supports 
development of the future outflow tract (OFT), ventricular septum, and the remainder of the atria and right 
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ventricle22. Cells of the FHF originate in splanchnic mesoderm of the anterior lateral plate and in response 
to inductive signals from adjacent endoderm become the first cardiac precursors to differentiate23. 
Gastrulation movements help to facilitate, positioning the cardiogenic mesoderm as bilateral folds 
alongside the prechordal plate. By 17-19 days, the cardiogenic folds coalesce anteriorly to form the 
cardiac crescent, a transient structure that will fuse and detach from the dorsal pericardial wall as a linear, 
bilaminar heart tube. Subsequent establishment of axial left-right asymmetries directs asymmetric growth 
and rightward looping of the heart tube, properly positioning the heart for future chamber and valve 
development. While these movements are occurring, cells from the SHF have already begun migrating 
from positions dorsal and posterior to the heart tube to support elongation of the arterial and venous 
poles. During weeks six and seven, an epithelial to mesenchymal transition populates the common 
atrioventricular canal and OFT with loose mesenchymal cell populations called endocardial cushions. 
Mature valves arise through extensive cushion remodeling and become highly stratified into distinct 
layers. Meanwhile, neural crest cells delaminate from the dorsal neural tube and migrate into the 
developing OFT  to support septation of the great vessels, as well as maturation of the aortic and 
pulmonary valves24. Significant cardiac contributions are also made by cells of the proepicardium, which 
originate from venous coelomic mesothelium and support development of the future epicardium and 
coronary vasculature25. As development nears completion, the heart is refined into a muscular, four-
chambered organ capable of regulating incoming and outgoing blood flow by way of divided inflow and 
outflow tracts and mature valve and conduction systems.   
 
Complex signaling and transcriptional networks regulate heart development: 
 These embryonic events are tightly regulated by an extensive array of signaling pathways and 
transcription factors. Several recent publications have reviewed the roles of these networks throughout all 
major stages of cardiac development15-18, 26. Therefore, the intent here will not be to reproduce these 
comprehensive works, but rather to highlight general mechanisms.  
Every major developmental pathway contributes in some capacity to heart development (Table 
1), often through extensive cross-talk with other signals or molecular factors. The impact of a particular 
signal can vary dramatically as development proceeds, operating positively at one stage and negatively at 
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another. For example, Bmp signaling is required to induce differentiation of early cardiac progenitors, but 
is inhibited at later stages by Smad6a to permit Tbx2- and Tbx20-mediated chamber development27. 
Similarly, mouse studies have demonstrated that Wnt signals are critical for early cardiac precursor 
induction and proliferation, but later become inhibitory28, 29. As previously mentioned, a diverse array of 
cardiac transcription factors acts in concert with these signals to specify, differentiate, and pattern the 
developing heart. Clinical genetic testing is available for many of these factors and is summarized in 
Table 2. The resulting web of interactions supports a highly complex milieu in which individual or multiple 
risk factors can act to disrupt normal heart morphogenesis. An ideal example is provided by the cardiac 
transcription factor, Nkx2.5, which has key functions in regulating proliferation of SHF cells through 
repression of Bmp2 signaling30 and in conduction system development31. Nkx2.5 also physically and 
functionally interacts with the major cardiac transcription factors Gata432, Tbx533, and Mef2c34, each of 
which forms additional unique and shared connections with other molecular, genetic, and signaling 
components (Figure 1). Such networks also hint at “common disease-common variant” hypotheses and 
the implication that some CHD phenotypes may result from additive effects of multiple low-effect 
susceptibility alleles. Following identification of two disease-associated haplotypes in large Caucasian 
and African American cohorts35, the SHF marker / Lim-homeodomain transcription factor, ISL1, has 
emerged as a possible susceptibility candidate. Although the pathogenicity of at least one of the reported 
variants remains uncertain36, 37, these studies highlight a growing recognition of the potential for common 
alleles to contribute to CHD pathogenesis.  
    
GENETICS AND RECURRENCE: 
Contemporary advancements in medical care, surgical interventions, and diagnostics have 
contributed to a well-characterized decrease in patient mortality and concomitant increase in CHD 
prevalence among patients of reproductive age38-40. Recent analyses indicate that adults now constitute 
roughly two-thirds of the CHD population, representing a nearly 60% increase in CHD prevalence among 
adult patients since the year 200038. The fact that the greatest increase in CHD prevalence has occurred 
among the 18- to 40-year-old demographic38 has clear implications for heritability. 
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 Large-scale epidemiologic studies suggest that a genetic or environmental cause for CHD is 
identifiable in approximately 20-30% of cases41-43. Known genetic causes are extremely heterogeneous, 
encompassing not only mutations in cardiac-relevant genes, but also more complex chromosomal 
abnormalities, submicroscopic duplications/deletions, and whole chromosome aneuploidies (Table 3). As 
genetic testing technologies have evolved to offer higher resolutions and greater diagnostic yields than 
those provided by conventional chromosomal analyses, copy number variants (CNVs) have emerged as 
important causes of both syndromic and non-syndromic CHDs9. Moreover, an increasing recognition of 
contributing environmental10, 11 and epigenetic12, 13 factors has revealed a previously unanticipated 
breadth to CHD etiology.  Families with Mendelian inheritance have been useful for identifying monogenic 
causes, although mutations in identified genes have been infrequently detected in unrelated patient 
cohorts44. Autosomal dominant, autosomal recessive, and X-linked inheritance patterns have all been 
reported, often in the context of additional non-cardiac malformations or syndromic disease, and each 
pose unique recurrence risks for affected families (Table 4). Improvements in diagnostic fidelity offered by 
chromosomal microarray analysis (CMA) and fluorescence in-situ hybridization (FISH) have additionally 
facilitated re-diagnosis of many patients with syndromic disease previously thought to have isolated 
CHD45. Establishment of an accurate genetic diagnosis is of critical importance, holding significant 
implications for not only medical management and long-term follow-up, but also for communication of 
relevant reproductive risks and family planning.  
In general, recurrence estimates are more precise for syndromic than for isolated CHDs as 
inheritance patterns for many CHD-associated genetic conditions are already well characterized (Table 
4). For dominantly inherited conditions, such as Noonan or Holt-Oram syndromes, individual recurrence 
risks for offspring with the syndrome is 50%. Genetic testing is also indicated for male offspring in families 
with X-linked heterotaxy caused by mutations in ZIC3, as they also have a 50% recurrence risk. 
Importantly not all patients with a particular syndrome will present with associated heart defects and the 
proportion that do can vary considerably depending on the specific diagnosis (Table 4). The presence or 
severity of a CHD in a parent is also not predictive of the risk for offspring. The prevalence of CHDs in a 
population caused by a particular syndrome ultimately depends on the likelihood of affected individuals 
reaching reproductive age and the new mutation rate. Consequently, despite having relatively high rates 
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of associated CHDs, patients with lethal conditions such as Edwards Syndrome (Trisomy 18) or Patau 
Syndrome (Trisomy 13) contribute less to overall population CHD burden than patients with less severe, 
but more prevalent conditions.  
Recurrence risks for isolated CHDs can be difficult to assign. This is especially true when the 
disease phenotype is complicated by reduced penetrance and variable expressivity, both of which are 
common. Indeed, dramatically different CHD phenotypes can be exhibited by patients with identical 
mutations, even among members of the same family. Nevertheless, consistent evidence of familial 
clustering and high heritability of isolated CHDs indicate that a strong genetic component exists, even for 
defects occurring without an obvious mode of inheritance46-49. Increased rates of CHDs among offspring 
of consanguineous unions have been noted in several populations and are commonly attributed to 
autosomal recessive mutations in associated disease genes (reviewed in Shieh et al50). Long-standing 
CHD models consider a large subset of CHDs to be multifactorial in origin, resulting from combined 
interaction of a number of distinct environmental and genetic factors51. Several large-scale 
epidemiological studies have examined rates of recurrence among first degree relatives of patients with 
isolated CHDs and collectively suggest an overall risk of 5-10% for any CHD when either one parent or 
more than two siblings are affected52-54. This figure reduces to ~3% with a single affected child. Risk 
estimates for individual defects vary, but are generally estimated in the range of 2-6%, with higher risk 
afforded to children of affected mothers (Table 5). These figures are low relative to CHDs with 
demonstrable monogenic inheritance, but can still have potentially important implications, particularly with 
respect to future reproductive decision-making and prospective screening of presumably unaffected 
family members.  
 
DIAGNOSTIC EVALUATION: 
Genetic testing algorithm for CHD: 
Genetic testing practices for CHDs have yet to be standardized in many centers and 
recommendations incorporating newer genetic testing technologies are, at present, poorly represented in 
the literature. In addition, there is evidence that genetic testing is frequently underutilized in infants with 
CHD55, 56. Nevertheless, the importance of genetic evaluation of patients with CHD has been emphasized 
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in a position statement from the American Heart Association57, which cites four specific reasons to pursue 
testing: 
(1) there may be other important organ system involvement,  
(2) there may be prognostic information for clinical outcomes,  
(3) there may be important genetic reproductive risks the family should know about; and  
(4) there may be other family members for whom genetic testing is appropriate.  
In Figure 2, we suggest a genetic testing algorithm that could be instituted in infants with CHD to provide 
a more comprehensive and standardized approach. This algorithm is derived from extensive clinical 
experience and has been used at our institution since 2009. These recommendations were explicitly 
created to guide cardiac care practitioners in determining appropriate genetic testing and referral 
strategies for cardiac intensive care unit (CICU) patients. Practitioners should evaluate guidelines most 
appropriate for their institution with a goal of practicing evidence-based medicine. In our center, 
geneticists consult patients with syndromic or suspected syndromic CHD and genetic counselors facilitate 
genetic testing in patients with apparently isolated CHD for whom testing is indicated and expedite 
appropriate cardiac screening in first degree relatives. Ongoing multicenter registries aimed at refining the 
interpretation of clinical CMA findings, such as the Clinical Genome Project and the Cytogenomics of 
Cardiovascular Malformations Consortium, will continue to improve the diagnostic yield and interpretation 
of abnormal CMA in patients with CHD.  
 
Genetic services and counseling: 
Recent surveys of adult CHD populations have demonstrated that a majority of patients lack 
proper understanding of their personal recurrence risks, but that provision and recall of genetic 
information can be significantly improved by incorporating genetic services into routine cardiovascular 
care58, 59. Genetic counselors skilled in cardiovascular genetics have, consequently, become an 
invaluable clinical asset, helping to not only provide accurate recurrence risks, but also to obtain family 
and medical histories, facilitate appropriate genetic testing, interpret test results, make necessary 
subspecialty referrals, and provide attendant psychosocial support for patients and their families60. The 
importance of the cardiologist in promoting genetic services cannot be understated: most patients first 
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hear about the possibility of genetic consultation from their cardiologist and a majority of these patients 
retroactively view the resulting genetics appointments positively58, 59. These findings are particularly 
relevant in light of results from a non-scientific poll recently conducted at the 21st Annual International 
Adult Congenital Heart Disease (ACHD) Course which suggest that only 18% of ACHD practitioners 
regularly refer their patients for genetic evaluation and that only 25% regularly work alongside genetic 
counselors and clinical geneticists60. Continued integration of genetic professionals into existing and new 
cardiovascular programs will undoubtedly help to improve utilization of increasingly comprehensive and 
affordable genetic services. 
 
GENETIC TESTING AND EMERGING TECHNOLOGIES: 
Chromosomal analyses and copy number variation: 
Genetic testing technologies have progressed considerably in recent years with novel sequencing 
and chromosome-based methods improving both the speed and breadth of available testing options. 
Although karyotyping remains the gold standard for diagnosis of aneuploidies and other large 
chromosomal abnormalities, cytogenetic methods such as FISH and CMA have proven invaluable in 
identifying microdeletion and duplication syndromes resulting from abnormalities too small to be detected 
by conventional chromosomal analyses (Table 6). These developments are significant: an ever-growing 
body of studies indicate that pathogenic CNVs are a major cause of CHDs, occurring in 3-25% of patients 
with extra-cardiac abnormalities and in 3-10% of patients with isolated heart defects (reviewed in Lander 
et al.9). In practice, the relatively limited resolutions of karyotyping and FISH have rendered them 
insufficient to detect a genetic cause in the majority of patients with CHDs of uncertain etiology55 and in 
nearly half of all patients with syndromic CHD61. Therefore, use of CMA as a higher fidelity option for first-
line CHD genetic testing has been recommended, particularly when extra-cardiac features are present 
and a suspected diagnosis is lacking61.  
This opinion has been strongly supported by additional clinical and research studies assessing 
diagnostic yields in selected cohorts55, 56, 62-65. In our retrospective analysis, CMA testing detected 
cytogenetic abnormalities of clinical or unknown significance in 35/121 (29%) infants with CHD56, 
representing rates on par with those observed in patients undergoing testing for intellectual disability66, 67, 
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for which CMA is already a first-line diagnostic test. Because most causal CNVs in patients with 
syndromic CHD are readily detectable by even low-resolution CMAs, and because significant increases in 
CMA resolution may not always translate to higher diagnostic yields68, physicians encountering patients 
with potentially syndromic phenotypes, but normal CMA results, would be prudent to rule out the 
possibility of a previously missed monogenic cause. Supporting this recommendation, Breckpot et al.55 
identified 7% of patients in their cohort with normal CMA results who were later found to have a single-
gene disorder on follow-up.  
 
Next-generation sequencing and whole exome analysis: 
Genetic technologies are advancing at such a rapid pace that keeping abreast of methodological 
advancements and emerging clinical applications has become both more essential and more challenging 
than ever before. Arguably the most significant development in recent years has been the advent of 
massively parallel next-generation sequencing (NGS) technologies, which encompass an assortment of 
commercially and methodologically distinct services that share similar foundations in repeated 
sequencing of DNA fragments (reviewed in Dorn et al.69, with a focus on CHD). Millions of individual 
sequences (“reads”) are generated in simultaneous reactions and are subsequently aligned to form a 
completed sequence. These techniques facilitate considerably higher depths of coverage, faster 
turnaround times, and increased cost-effectiveness when compared to traditional capillary-based 
sequencing methods70, 71. Although Sanger sequencing remains the gold standard for targeted analyses 
of specific genes or familial mutations, it requires a priori knowledge of causative disease genes or 
sequences and does not contribute to novel gene discovery. Additionally, most gene panels are disease-
specific, necessitating implementation of large numbers of distinct assays.  Conversely, like CMA, NGS 
approaches provide greater diagnostic utility for suspected genetic disease of uncertain etiology and for 
genetically heterogeneous conditions stemming from mutations in larger numbers of causative loci. One 
of the biggest benefits of this technology has been its scalability - both to large-scale whole 
genome/exome analyses and to smaller gene-specific targeted studies. This flexibility has initiated a 
paradigm shift towards adoption of NGS in both clinical and research settings and has, even in its relative 
infancy, greatly benefited novel disease gene discovery and patient diagnosis72-76. 
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Nowhere is this shift more apparent than in the increased clinical implementation of whole exome 
sequencing (WES)73. In contrast to whole genome sequencing (WGS), which interrogates every base in 
the genome, WES specifically targets protein-encoding genomic regions and makes the implicit 
assumption that a significant proportion of uncharacterized genetic disease can be explained by 
sequence variation in coding DNA.  This assumption is reasonable for many inherited conditions as most 
mutations resulting in Mendelian disease have been traditionally detected in protein-coding regions77-79. In 
addition, our current ability to interpret the functional significance of variants in non-coding regions is 
relatively primitive57. Importantly, WES has been demonstrated to be both robust and cost-effective80, 
necessitating only 5% of the total sequencing required by GWS81. Adoption of WES has consequently 
been swift: since its clinical debut in 2011, most major genetic centers have established WES as a testing 
option for patients with complex phenotypes for whom traditional single and multi-gene panels were 
unrevealing, prohibitively expensive, or otherwise unavailable. Although these programs are still young, 
initial studies have reported deleterious mutation detection rates in the range of 20-50%72, 82, 83, indicating 
significant potential for high diagnostic yields. WES has already been used successfully to identify genetic 
defects associated with a diverse spectrum of CHDs84-87. Interpretation of detected variants, however, 
remains a major challenge as WES identifies, on average, 12,000 unique coding variants per exome 
sequenced88 and potentially pathogenic variants are observed even in apparently healthy individuals89-91. 
It is expected that reporting laboratories will perform a thorough literature review for all variants of 
potential clinical relevance and properly classify each as having known or uncertain significance.  
While WES is clearly beneficial in multiple settings, its use as a first-tier test has generated  
debate, with concerns raised over not only interpretation and reporting of clinically relevant mutations, but 
also return of incidental findings, availability of insurance coverage, and cost effectiveness relative to 
existing multi-gene panels72, 92.  Thus, it is important that care providers familiar both with the strengths 
and limitations of WES and its applicability to the patient’s phenotype(s) be involved in facilitating testing. 
It is anticipated that the already widespread application of WES will lead to improvements in existing 
technologies, decreasing overall costs and increased insurance coverage. 
 
 
13 
 
Future developments: 
To date, clinical application of NGS has largely been restricted to analysis of genomic variation. 
Nevertheless, the same technologies employed for DNA-based analyses can be used to interrogate a 
variety of other disease-relevant processes, including RNA expression, alterations in splicing, epigenetic 
regulation, and protein-nucleotide interactions (eg: transcription factor binding)93. These applications hold 
considerable future diagnostic and clinical potential and are already providing great utility for investigators 
applying comprehensive system-based approaches to the study of CHD94, 95. The recognition that multiple 
independent insults are likely to contribute to at least a subset of CHD phenotypes indicate that systems-
based approaches will be necessary to understand CHD risk factor networks and properly contextualize 
many genetic testing results, particularly in the absence of extra-cardiac features or clear syndromic 
diagnoses.  
 
SUMMARY: 
The field of CHD genetics is progressing at a rapid pace. The last decade in particular has 
witnessed unprecedented improvements in genetic testing technologies that have greatly assisted gene 
discovery and helped to reshape standards of patient care. These trends are likely to continue as testing 
costs continue to decline and genetic services become further integrated into new and existing 
cardiovascular programs. With the functional significance of much of the genome still undefined and the 
mechanisms driving both normal and abnormal heart development incompletely understood, 
interpretation and reporting of clinically relevant mutations will remain a major challenge for the 
foreseeable future. Accordingly, clinical geneticists and genetic counselors will need to play increasingly 
key roles in patient care, ensuring accurate diagnosis and effective communication of inheritance and 
recurrence risks. Despite, or perhaps because of, such challenges, this new era of unbiased, genome- 
and exome-based testing is an exciting one. Recent efforts integrating results from animal modeling 
studies with systems biology approaches indicate great potential for future developmental research, while 
collaborative endeavors such as the National Heart, Lung, and Blood Institute’s (NHLBI) Bench to 
Bassinet program (http://www.benchtobassinet.com/) aim to bridge the gap between basic research and 
clinical practice. The wealth of genetic data anticipated from these and other forward-thinking studies 
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promise to power novel hypotheses for future experimentation and to generate new avenues for potential 
therapeutic intervention. 
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BEST PRACTICES:  
  
Best Practices Box 
 
What is the current practice? 
 
Genetic Testing in Congenital Heart Disease: 
 
• Genetic testing practices for CHDs have yet to be standardized in many centers. 
• Recommendations incorporating newer genetic testing methods are poorly represented in the literature.  
• Genetic testing is frequently underutilized for infants with CHD. 
 
Genetic Testing Options: 
 
• Karyotyping is the gold standard for diagnosis of aneuploidies and other large chromosomal 
abnormalities. 
• Chromosomal microarray (CMA) and fluorescence in situ hybridization (FISH) permit identification of 
microdeletion and duplication syndromes resulting from abnormalities too small to be detected by 
conventional chromosome analyses. 
• Sanger sequencing is the gold standard for targeted molecular analysis of specific genes or familial 
mutations. Gene panels are available for many CHD-associated syndromes, but are limited by 
knowledge of causative disease genes. 
 
What changes in current practice are likely to improve outcomes? 
 
• Continued integration of genetic testing services into cardiovascular practice will improve diagnostic and 
prognostic accuracy and will support risk assessment and family planning initiatives. 
• Emerging next generation sequencing (NGS) technologies promise to greatly benefit patient diagnosis 
and gene discovery efforts. 
 
Is there a Clinical Algorithm? 
 
• Our proposed genetic testing algorithm is presented in Figure 2. 
•  In our center, geneticists consult patients with known or suspected syndromic CHD and genetic 
counselors facilitate genetic testing in patients with apparently isolated CHD and expedite appropriate 
screening in first degree relatives. 
 
Major Recommendations:  
 
Genetic testing and referral decisions should be determined based on the nature of the cardiac defect: 
 
1. Patients with defects suggesting a common chromosomal aneuploidy should undergo karyotyping and 
FISH testing. The patient should be referred for further genetic evaluation. 
2. Patients with multiple congenital anomalies, neurological findings, developmental delay, and/or 
dysmorphic features should also be referred for further genetics evaluation.  
3. Depending on the level of suspicion, patients with conotruncal defects should undergo CMA and/or 
targeted FISH testing for 22q11.2 deletion syndrome. 
4. A detailed pedigree should be obtained and CMA testing should be pursued for patients with apparently 
non-syndromic LVOTO, RVOTO, AVSD, heterotaxy, or other complex defects. Abnormal test results 
warrant referral for further genetics evaluation.  
 
Rating for the Strength of the Evidence:  
 
References: 
 
Pierpont ME, Basson CT, Benson DW, Jr., et al. Genetic basis for congenital heart defects: current knowledge. 
Circulation 2007;115:3015-38 (American Heart Association Position Statement). 
 
Summary: 
 
• Improvements in genetic testing technologies have assisted gene discovery and helped to reshape 
standards of patient care. These trends are expected to continue as testing costs decline and genetic 
services become further integrated into new and existing cardiovascular programs. 
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Figure 1: NKX2-5 forms a complex network of physical and genetic interactions with GATA4, TBX5, and 
MEF2C. The network diagram was generated using GeneMANIA software (http://www.genemania.org/). 
“GATA4, NKX-5, TBX5, and MEF2C” were used as query terms and results were weighted towards 
“biological process”. To maximize readability, output was restricted to 20 related genes. 
 
Figure 2: Proposed genetic testing algorithm for CHD. Genetic testing and referral decisions are 
determined based on the nature of the cardiac defect. If the defect is associated with features suggestive 
of a common chromosomal aneuploidy, karyotyping and FISH are undertaken and the patient is referred 
for evaluation by genetics. Likewise, patients with multiple congenital anomalies, neurological findings, 
developmental delay, and/or dysmorphic features all receive a genetics referral. Patients with isolated 
CHDs are stratified based on the nature of their individual phenotype. Those with conotruncal defects 
have testing for 22q11.2 deletion syndrome via CMA or targeted FISH testing depending on the level of 
suspicion. Apparently non-syndromic patients with LVOTO, RVOTO, AVSD, heterotaxy, and other 
complex defects have a detailed pedigree and CMA testing, as indicated. First degree relatives of 
patients with LVOTO defects are referred for cardiac screening. Abbreviations: ASD = atrial septal defect, 
AVSD = atrioventricular septal defect, CMA = chromosomal microarray analysis, FISH = fluorescence in 
situ hybridization, IAA = interrupted aortic arch, LVOTO/RVOTO = left/right ventricular outflow tract 
obstruction, TOF = Tetralogy of Fallot, VSD = ventricular septal defect, TrA = truncus arteriosus 
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Table 1: Signaling pathways involved in heart development 
Pathway Developmental Role(s) 
BMP Cardiac mesoderm induction 
Cardiac progenitor specification / differentiation 
 OFT septation 
Myocardial trabeculation 
AV canal development 
EC / valve development 
EGF Myocardial trabeculation 
EC / valve development 
FGF Cardiac mesoderm induction 
Cardiac progenitor specification / differentiation 
 SHF development 
EC / valve development 
Hedgehog Cardiac progenitor specification 
Heart looping / L-R patterning  
SHF development / OFT septation 
AV septation 
EC / valve development 
NCC development 
MAPK Cardiac mesoderm induction 
OFT development 
EC / valve development 
NCC development 
Notch Cardiac progenitor specification / differentiation 
Heart looping / L-R patterning 
OFT development 
Myocardial trabeculation 
AV canal / EC / valve development 
NCC development 
RA Cardiac progenitor proliferation  
Heart tube formation / looping 
A-P cardiac patterning 
SHF development 
Myocardial trabeculation 
TGF-β / Nodal Cardiac mesoderm induction 
Cardiac progenitor specification 
Heart looping / L-R patterning 
VEGF OFT septation 
EC / valve development 
Wnt (Canonical) Cardiac progenitor proliferation 
OFT septation 
EC / valve development 
Wnt (Non-canonical) Cardiac mesoderm induction  
Cardiac progenitor specification  
SHF / OFT development 
Abbreviations: A-P = anterior-posterior, AV = atrioventricular, BMP = bone morphogenetic protein, EC = 
endocardial cushion, EGF = epidermal growth factor, ERK = extracellular signal-regulated kinase, FGF = 
fibroblast growth factor, L-R = left-right, MAPK = mitogen-activated protein kinase, NCC = neural crest 
cell, OFT = outflow tract, RA = retinoic acid, SHF = second heart field, TGF-β = transforming growth 
factor-beta, VEGF = vascular endothelial growth factor, Wnt = wingless type 
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Table 2: Clinical testing availability for transcription factors associated with CHD 
Gene  Protein  Associated Syndrome(s) Clinical Testing Available?1 
ALX3 Aristaless-Like Homeobox 3 Frontonasal Dysplasia Yes 
ANKRD1 Ankyrin Repeat Domain 1 Dilated Cardiomyopathy Yes 
ARX Aristaless Related Homeobox 
X-Linked Lissencephaly with 
Ambiguous Genitalia; Epileptic 
Encephalopathy, Early Infantile, 1; 
Agenesis of Corpus Callosum with 
Abnormal Genitalia 
Yes 
CITED2 
Cbp/P300-Interacting 
Transactivator, With Glu/Asp-Rich 
Carboxy-Terminal Domain, 2 
Isolated CHD No 
ETS1 V-Ets Avian Erythroblastosis Virus E26 Oncogene Homolog 1 Isolated CHD No 
EVC1 Ellis Van Creveld Syndrome 1 Ellis-van Creveld Syndrome; Weyers Acrofacial Dystosis Yes 
EVC2 Ellis Van Creveld Syndrome 2 Ellis-van Creveld Syndrome Yes 
EYA1 Eyes Absent Homolog 1 Branchiootorenal Syndrome; Otofaciocervical Syndrome Yes 
FOXC1 Forkhead Box C1 Iridogoniodysgenesis, Type 1; Axenfeld-Rieger Syndrome, Type 3 Yes 
FOXC2 Forkhead Box C2 Lymphedema-Distichiasis Syndrome Yes 
FOXH1 Forkhead Box H1 Holoprosencephaly Yes 
FOXP1 Forkhead Box P1 Mental Retardation with Language Impairment and Autistic Features Yes 
GATA4 GATA Binding Protein 4 Isolated CHD Yes 
GATA5 GATA Binding Protein 5 Isolated CHD Yes 
GATA6 GATA Binding Protein 6 Isolated CHD Yes 
HAND1 Heart And Neural Crest Derivatives Expressed 1 Isolated CHD No 
HAND2 Heart And Neural Crest Derivatives Expressed 2 Isolated CHD No 
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HOXA1 Homeobox A1 
Athabaskan Brain Stem Dysgenesis 
Syndrome; Bosley-Salih-Alorainy 
Syndrome 
Yes 
IRX4 Iroquois Homeobox 4 Isolated CHD No 
MED12 Mediator Complex Subunit 12 FG Syndrome Type 1; Lujan-Fryns Syndrome Yes 
MED13L Mediator Complex Subunit 13-Like Isolated CHD No 
MEF2C Myocyte Enhancer Factor 2C 
Mental Retardation, Stereotypic 
Movements, Epilepsy, and/or 
Cerebral Malformations 
Yes 
MESP1 Mesoderm Posterior 1 Homolog Isolated CHD No 
MYCN 
V-Myc Avian Myelocytomatosis 
Viral Oncogene Neuroblastoma 
Derived Homolog 
Feingold Syndrome 1 Yes 
MYOCD Myocardin Isolated CHD No 
NFATC1 
Nuclear Factor Of Activated T-
Cells, Cytoplasmic, Calcineurin-
Dependent 1 
Isolated CHD No 
NKX2-5 NK2 Homeobox 5 Isolated CHD Yes 
NKX2-6 NK2 Homeobox 6 Isolated CHD Yes 
PAX3 Paired Box 3 
Waardenburg Syndrome Type I, 
Type 3; Craniofacial-Deafness-Hand 
Syndrome 
Yes 
PITX2 Paired-Like Homeodomain 2 Axenfeld-Rieger Syndrome Yes 
SALL1 Spalt-Like Transcription Factor 1 Townes-Brocks Syndrome Yes 
SALL4 Spalt-Like Transcription Factor 4 Duane-Radial Ray Syndrome; Acro-Renal-Ocular Syndrome Yes 
SETBP1 SET Binding Protein 1 Schinzel-Giedion Midface Retraction Syndrome Yes 
SIX6 SIX Homeobox 6 Microphthalmia with Cataract 2 Yes 
SOX2 Sex Determining Region Y-Box 2 Anophthalmia/Microphthalmia Yes 
SOX9 Sex Determining Region Y-Box 9 Campomelic Dysplasia Yes 
TBX1 T-Box 1 22q11.2 Deletion Syndrome Yes 
TBX3 T-Box 3 Ulnar-Mammary Syndrome Yes 
TBX5 T-Box 5 Holt-Oram Syndrome Yes 
TBX20 T-Box 20 Isolated CHD Yes 
TFAP2B Transcription Factor AP-2 Beta Char Syndrome Yes 
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1Accurate as of 7/24/2014; Source: Genetests (http://www.genetests.org/)  
  
TP63 Tumor Protein P63 
ADULT syndrome, Ectrodactyly, 
ectodermal dysplasia, and cleft 
lip/palate syndrome 3; Hay-Wells 
syndrome; Limb-mammary 
Syndrome; Rapp-Hodgkin syndrome 
Yes 
TWIST1 Twist Family BHLH Transcription Factor 1 Saethre-Chotzen Syndrome Yes 
ZEB2 Zinc Finger E-Box Binding Homeobox 2 Mowat-Wilson Syndrome Yes 
ZFPM2 Zinc Finger Protein, FOG Family Member 2 Isolated CHD Yes 
ZIC3 Zic Family Member 3 Heterotaxy Syndrome; VACTERL Yes 
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Table 3: Etiology of congenital heart disease  
Genetic Cause % CHD Attributed References 
Single gene 3-5% 96 
Chromosomal / Aneuploidy 8-10% 96, 97 
Copy Number Variation 3-25% (Syndromic), 3-10% (Isolated) 9 
Environmental 2% 11 
Multifactorial Unknown, estimated 80-85% 97, 98 
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Table 4: Examples of common syndromes associated with CHD  
Data from 19, 99 and Genereviews8 
1Abbreviations: AD = autosomal dominant, AR = autosomal recessive 
2Abbreviations: AS = aortic stenosis, ASD = atrial septal defect, AVC = atrioventricular canal, BAV = 
bicuspid aortic valve disease, CoA = coarctation of the aorta, HCM = hypertrophic cardiomyopathy, HLHS 
= hypoplastic left heart syndrome, IAA = interrupted aortic arch, PAPVD = partial anomalous pulmonary 
venous drainage, PDA = patent ductus arteriosus, PPS = peripheral pulmonary stenosis, PS = pulmonary 
stenosis, SVAS = supravalvular aortic stenosis, TrA = truncus arteriosus, TOF = Tetralogy of Fallot, VSD 
= ventricular septal defect.  
  
Syndrome Live-birth Prevalence Genetic Etiology Inheritance
1 Cardiac Phenotype (% 
Patients with CHD)2 
Aneuploidies 
Down 
syndrome 1/1000 Trisomy 21 Typically sporadic (RR = ≤1%) 
ASD, AVC, PDA, VSD (40-
50%) 
Turner 
syndrome 
1/2,000-
1/5,000 45, X Typically sporadic (RR = ≤1%) 
Left-sided defects: Aortic 
dilatation, AS, BAV, CoA, 
HLHS, PAPVD (15-50%) 
Edward 
syndrome 1/6000 Trisomy 13 Typically sporadic (RR = ≤1%) 
ASD, PDA, polyvalvular 
disease, VSD (80-100%) 
Patau 
syndrome 
1/10,000-
1/20,000 Trisomy18 Typically sporadic (RR = ≤1%) 
ASD, PDA, polyvalvular 
disease, VSD (80-100%) 
Microdeletion/duplication syndromes 
22q11.2 
microdeletion 
syndrome 
1/4,000 22q11.2 deletion Majority de novo, AD when inherited (RR = 50%) 
Conotruncal defects: IAA 
type B, TrA, TOF, VSD 
(75-80%) 
Willams-
Beuren 
syndrome 
1/7,500-
1/20,000 
7q11.23 del, incl. 
ELN gene 
Majority de novo, AD when 
inherited (RR = 50%) 
AS (especially SVAS), 
PPS, valve defects (80-
100%) 
Singe gene disorders 
Noonan or 
Noonan-like 
syndrome  
1/1,000-
1/2,500 
PTPN11, SOS1, 
RAF1, KRAS, 
HRAS, NRAS, 
BRAF, MAP2K1, 
MAP2K2, SHOC2 
25-70% de novo, AD when 
inherited (RR = 50%), rarely 
AR (RR =25%).  
ASD, HCM, PDA, PS, 
VSD (80-90%) 
CHARGE 1/8,500-1/10,000 CHD7, SEMA3E 
Majority de novo, AD when 
inherited (RR = 50%) ASD, TOF, VSD (50-85%) 
Holt-Oram 
syndrome 1/100,000 TBX5 
~85% de novo, AD  
(RR = 50%) 
ASD, conduction defects 
VSD (75-85%) 
Alagille 
syndrome 1/100,000 JAG1, NOTCH2 
50-70% de novo, AD (RR = 
50%) 
AS, ASD, PPS, PS TOF, 
VSD (85-95%) 
Costello 
syndrome 
1/300,000-
1/1,250,000 HRAS 
Majority de novo, AD when 
inherited (RR = 50%) 
Arrhythmias, HCM, PS 
(>60%) 
Char 
syndrome 
Unknown, 
rare TFAP2B 
% de novo unknown, AD when 
inherited (RR = 50%) PDA (100%) 
Cardiofaciocu
taneous 
syndrome 
Unknown, 
rare 
BRAF, MAP2K1, 
MAP2K2, KRAS 
Majority de novo, AD when 
inherited (RR = 50%) 
ASD, HCM, PS, VSD 
(~70%) 
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Table 5: Recurrence risks for isolated (non-syndromic) CHDs (%) 
Defect Father Affected Mother Affected 1 Sibling Affected 2 Siblings Affected 
ASD 1.5-3.5 4-6 2.5-3 8 
AVSD 1-4.5 11.5-14 3-4 10 
VSD 2-3.5 6-10 3 10 
AS 3-4 8-18 2 6 
PS 2-3.5 4-6.5 2 6 
TOF 1.5 2-2.5 2.5-3 8 
CoA 2-3 4-6.5 2 6 
PDA 2-2.5 3.5-4 3 10 
HLHS 2148 2 6 
TGA 297 1.5 5 
L-TGA 3-597 5-6 NR 
EA NR 697 1 3 
TrA NR NR 1 3 
TA NR NR 1 3 
PA NR NR 1 3 
Data from 52-54 except where otherwise noted. NR = not reported/insufficient data 
Merged cells indicate recurrence when one parent is affected, irrespective of gender, and are used in the 
absence of gender-stratified risks.  
Abbreviations: ASD = atrial septal defect, AS = aortic stenosis, AVSD = atrioventricular septal defect, CoA 
= coarctation of the aorta, EA = Ebstein’s Anomaly, HLHS = hypoplastic left heart syndrome, L-TGA = 
congenitally corrected transposition of the great arteries, PDA = patent ductus arteriosus, PA = pulmonary 
atresia, PS = pulmonary stenosis, TA = tricuspid atresia, TGA = transposition of the great arteries, TOF = 
Tetralogy of Fallot, TrA = truncus arteriosus, VSD = ventricular septal defect 
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Table 6: Types of Genetic Tests for CHDs 
Test Type Target Resolution Detects 
Karyotyping Cytogenetic Genome >10Mb Aneuploidies, chromosomal abnormalities 
FISH Cytogenetic Chromosomal region >20kb 
Aneuploidies, chromosomal 
abnormalities 
CMA (aCGH, 
SNP arrays) Molecular Genome 5kbp 
SNPs, CNVs and other 
submicroscopic rearrangements 
Sanger 
sequencing Molecular Gene-specific Single-base SNPs, indels 
WGS/WES Molecular Genome/Exome Single-base SNPs, indels, CNVs1 
1Detection of indels and CNVs can be difficult using current technology. Bioinformatics capabilities are emerging. 
Abbreviations: aCGH = array comparative genomic hybridization, CMA = chromosome microarray analysis, CNVs 
= copy number variants, FISH = fluorescence in situ hybridization, SNPs = single nucleotide polymorphisms, WES 
= whole exome sequencing, WGS = whole genome sequencing 
 
 
 
